Time-Varying Dark Energy Constraints From the Latest SN Ia, BAO and SGL

Based on the latest SNe Ia data provided by Hicken et al. (2009) with using MLCS17 light curve fitter, together with the Baryon Acoustic Oscillation(BAO) and strong gravitational lenses(SGL), we investigate the constraints on the dark energy equation-of-state parameter $w$ in the flat universe, especially for the time-varying case $w(z)=w_0+w_zz/(1+z)$. The constraints from SNe data alone are found to be: (a) $(\Omega_M, w)=(0.358, -1.09)$ as the best-fit results; (b) $(w_0, w_z)=(-0.73^{+0.23}_{-0.97}, 0.84^{+1.66}_{-10.34})$ for the two parameters in the time-varying case after marginalizing the parameter $\Omega_M$; (c) the likelihood of parameter $w_z$ has a high non-Gaussian distribution; (d) an extra restriction on $\Omega_M$ is necessary to improve the constraint of the SNe Ia data on the parameters ($w_0$, $w_z$). A joint analysis of SNe Ia data and BAO is made to break the degeneracy between $w$ and $\Omega_M$, and leads to the interesting maximum likelihoods $w_0 = -0.94$ and $w_z = 0$. When marginalizing the parameter $\Omega_M$, the fitting results are found to be $(w_0, w_z)=(-0.95^{+0.45}_{-0.18}, 0.41^{+0.79}_{-0.96})$. After adding the splitting angle statistic of SGL data, a consistent constraint is obtained $(\Omega_M, w)=(0.298, -0.907)$ and the constraints on time-varying dark energy are further improved to be $(w_0, w_z) = (-0.92^{+0.14}_{-0.10}, 0.35^{+0.47}_{-0.54})$, which indicates that the phantom type models are disfavored.Comment: 24 pages, 9 figures, to be published in JCA

Dendritic Core-Shell Macromolecules Soluble in Supercritical Carbon Dioxide

International audienceSupercritical carbon dioxide has found strong interest as a reaction medium recently.1,2 As an alternative to organic solvents, compressed carbon dioxide is toxicologically harmless, nonflammable, inexpensive, and environmentally benign.3 Its accessible critical temperature and pressure (Tc ) 31 °C, Pc ) 7.38 MPa, Fc ) 0.468 g cm-3)4 and the possibility of tuning the solvent-specific properties between the ones of liquid and gas are very attractive

Quintessence with a constant equation of state in hyperbolic universes

Quintessence models leading to a constant equation of state are studied in hyperbolic universes. General properties of the quintessence potentials V(phi) are discussed, and for some special cases also the exact analytic expressions for these potentials are derived. It is shown that the observed angular power spectrum of the cosmic microwave background (CMB) is in excellent agreement with some of the quintessence models even in cases with negative curvature. It is emphasized that due to a (w_phi, Omega_phi, Omega_c)-degeneracy a universe with negative spatial curvature cannot be excluded.Comment: 15 pages, a version with figures in color can be obtained at http://www.physik.uni-ulm.de/theo/qc/ulm-tp/tp02-13.ps.g

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

К проблеме социальной эффективности инноваций в профессиональном образовании

Movile Cave, Romania, is an unusual underground ecosystem that has been sealed off from the outside world for several million years and is sustained by non-phototrophic carbon fixation. Methane and sulfur-oxidising bacteria are the main primary producers, supporting a complex food web that includes bacteria, fungi and cave-adapted invertebrates. A range of methylotrophic bacteria in Movile Cave grow on one-carbon compounds including methylated amines, which are produced via decomposition of organic-rich microbial mats. The role of methylated amines as a carbon and nitrogen source for bacteria in Movile Cave was investigated using a combination of cultivation studies and DNA stable isotope probing (DNA-SIP) using 13C-monomethylamine (MMA). Two newly developed primer sets targeting the gene for gamma-glutamylmethylamide synthetase (gmaS), the first enzyme of the recently-discovered indirect MMA-oxidation pathway, were applied in functional gene probing. SIP experiments revealed that the obligate methylotroph Methylotenera mobilis is one of the dominant MMA utilisers in the cave. DNA-SIP experiments also showed that a new facultative methylotroph isolated in this study, Catellibacterium sp. LW-1 is probably one of the most active MMA utilisers in Movile Cave. Methylated amines were also used as a nitrogen source by a wide range of non-methylotrophic bacteria in Movile Cave. PCR-based screening of bacterial isolates suggested that the indirect MMA-oxidation pathway involving GMA and N-methylglutamate is widespread among both methylotrophic and non-methylotrophic MMA utilisers from the cave

Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study

To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked FilesBACKGROUND: In patients with systemic lupus erythematosus (SLE) there is no serological test that will reliably distinguish neuropsychiatric (NP) events due to active SLE from those due to other causes. Previously we showed that serum levels of nitrated nucleosomes (NN) were elevated in a small number of patients with NPSLE. Here we measured serum NN in samples from a larger population of patients with SLE and NP events to see whether elevated serum NN could be a marker for NPSLE. METHODS: We obtained serum samples from patients in the Systemic Lupus International Collaborative Clinics (SLICC) inception cohort. This included 216 patients with NP events and two matched controls with SLE but no NP events for each of these patients. For the NP patients we tested samples taken before, during and after the NP event. RESULTS: Twenty-six patients had events attributed to SLE according to the most stringent SLICC attribution rule. In these patients there was no association between onset of event and elevated serum NN. In 190 patients in whom events were not attributed to SLE by the SLICC rules, median serum NN was elevated at the onset of event (P = 0.006). The predominant clinical features in this group of 190 patients were headache, mood disorders and anxiety. CONCLUSIONS: Serum NN levels rise at the time of an NP event in a proportion of patients with SLE. Further studies are needed to determine the value of serum NN as a biomarker for NPSLE.LUPUS UK Rosetrees Trust Arthritis Research UK Programme Grant National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre Canadian Institutes of Health Research Hanyang University Sandwell and West Birmingham Hospitals National Health Service (NHS) Trust IHR/Wellcome Trust Clinical Research Facility in Birmingham National Institutes of Health (NIH) Singer Family Fund for Lupus Research Arthritis Research UK National Institute for Health Research Manchester Biomedical Research Unit NIHR/Wellcome Trust Manchester Clinical Research Facility Danish Rheumatism Association Novo Nordisk Foundation NIH Department of Education, Universities and Research of the Basque Government Arthritis Research U